Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

Cephalon

Status and phase: Completed; Phase 2

Conditions: Mantle Cell Lymphoma

Treatments: Drug: Rituximab; Drug: Bendamustine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00891839

C18083/2039/NL/US-CA

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and safety of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma.

Enrollment: 45 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histopathologically confirmed diagnosis of typical or atypical mantle cell lymphoma, except for blastoid type.
• documented relapsed/refractory mantle cell lymphoma.
• CD20 positive B cells in the lymph node biopsy or other lymphoma pathology specimen.
• adequate hematologic function according to specific trial parameters.
• bidimensionally measurable disease with at least 1 lesion measuring 2.0 cm or more in a single dimension, or the patient is in the leukemic phase of the disease.
• patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• patient has an estimated life expectancy of at least 3 months.
• women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
• men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of study drug treatment and for 30 days after participation in the treatment period.

Exclusion criteria

• has received more than 3 previous standard chemotherapy regimens.
• has the blastoid subtype of mantle cell lymphoma.
• documented history of central nervous system (CNS) lymphomatous involvement.
• a history of previous high-dose chemotherapy with allogeneic stem cell transplantation (history of autologous stem cell transplantation is allowed).
• previous treatment with bendamustine.
• has an active malignancy other than MCL, or has had a malignancy other than MCL within the past 3 years, except for controlled prostate cancer without evidence of bone metastases, localized bladder cancer, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer.
• has New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or unstable angina, electrocardiographic evidence of active ischemia or active conduction system abnormalities, or myocardial infarction within the last 6 months.
• has serum creatinine of more than 2.0 mg/dL or creatinine clearance of less than 30 mL/min based on the Cockcroft-Gault method or from a 24-hour urine collection.
• does not have adequate hepatic organ function as evidenced by specific trial parameters.
• has known human immunodeficiency virus (HIV) infection.
• has active hepatitis B infection. Hepatitis B surface antigen must be tested.
• a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
• has received corticosteroids within 28 days of study entry unless chronically administered (prednisone ≤20 mg/day) for indications other than lymphoma or lymphoma-related complications.
• any serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to participate in or complete this study.
• any condition which places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
• patient has received other investigational agent(s) within 28 days of study entry.
• patient has received chemotherapy within the prior 28 days.
• patient has a known hypersensitivity to bendamustine, mannitol, or rituximab.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 1 patient group

Bendamustine+Rituximab

Experimental group

Description:

Patients receive bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2, and 375 mg/m\^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).

Treatment:

Drug: Rituximab

Drug: Bendamustine